IL299381A - Methods of treating neuromyelitis optica spectrum disorder - Google Patents
Methods of treating neuromyelitis optica spectrum disorderInfo
- Publication number
- IL299381A IL299381A IL299381A IL29938122A IL299381A IL 299381 A IL299381 A IL 299381A IL 299381 A IL299381 A IL 299381A IL 29938122 A IL29938122 A IL 29938122A IL 299381 A IL299381 A IL 299381A
- Authority
- IL
- Israel
- Prior art keywords
- subject
- need
- spectrum disorder
- neuromyelitis optica
- treatment
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Neurosurgery (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Neurology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biomedical Technology (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063046133P | 2020-06-30 | 2020-06-30 | |
| US202063052093P | 2020-07-15 | 2020-07-15 | |
| US202063071092P | 2020-08-27 | 2020-08-27 | |
| PCT/US2021/039911 WO2022006283A2 (en) | 2020-06-30 | 2021-06-30 | Methods of treating neuromyelitis optica spectrum disorder |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL299381A true IL299381A (en) | 2023-02-01 |
Family
ID=79321915
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL299381A IL299381A (en) | 2020-06-30 | 2021-06-30 | Methods of treating neuromyelitis optica spectrum disorder |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20230406928A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4172211A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2023534916A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20230030642A (cg-RX-API-DMAC7.html) |
| CN (1) | CN116234571A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2021299307A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112022026747A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3178954A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL299381A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2022016236A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2022006283A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7900888B2 (ja) * | 2020-10-29 | 2026-08-05 | ビエラ バイオ インコーポレイテッド | 自己免疫疾患を治療するための抗cd19抗体の使用 |
| CN117797245A (zh) * | 2023-12-29 | 2024-04-02 | 广州赛莱拉干细胞科技股份有限公司 | 人乳脂球表皮生长因子8用于制备治疗视神经脊髓炎谱系疾病药物中的应用 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101977843B1 (ko) * | 2017-02-16 | 2019-05-13 | 국립암센터 | 시신경척수염 및 다발성경화증의 선별을 위한 바이오마커 및 이의 이용 |
| CN110522908A (zh) * | 2018-05-25 | 2019-12-03 | 荣昌生物制药(烟台)有限公司 | TACI-Fc融合蛋白用于制备治疗视神经脊髓炎谱系疾病和多发性硬化之药物中的应用 |
| EP3959241A4 (en) * | 2019-04-24 | 2023-01-25 | Viela Bio, Inc. | USE OF AN ANTI-CD19 ANTIBODY TO TREAT AN AUTOIMMUNE DISEASE |
| JP7900888B2 (ja) * | 2020-10-29 | 2026-08-05 | ビエラ バイオ インコーポレイテッド | 自己免疫疾患を治療するための抗cd19抗体の使用 |
-
2021
- 2021-06-30 JP JP2022581408A patent/JP2023534916A/ja active Pending
- 2021-06-30 KR KR1020237002980A patent/KR20230030642A/ko active Pending
- 2021-06-30 MX MX2022016236A patent/MX2022016236A/es unknown
- 2021-06-30 CA CA3178954A patent/CA3178954A1/en active Pending
- 2021-06-30 EP EP21834411.7A patent/EP4172211A4/en active Pending
- 2021-06-30 WO PCT/US2021/039911 patent/WO2022006283A2/en not_active Ceased
- 2021-06-30 IL IL299381A patent/IL299381A/en unknown
- 2021-06-30 BR BR112022026747A patent/BR112022026747A2/pt unknown
- 2021-06-30 CN CN202180046409.5A patent/CN116234571A/zh active Pending
- 2021-06-30 AU AU2021299307A patent/AU2021299307A1/en active Pending
-
2022
- 2022-12-28 US US18/147,287 patent/US20230406928A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| BR112022026747A2 (pt) | 2023-01-24 |
| WO2022006283A2 (en) | 2022-01-06 |
| MX2022016236A (es) | 2023-03-29 |
| CA3178954A1 (en) | 2022-01-06 |
| KR20230030642A (ko) | 2023-03-06 |
| EP4172211A4 (en) | 2024-07-10 |
| EP4172211A2 (en) | 2023-05-03 |
| US20230406928A1 (en) | 2023-12-21 |
| WO2022006283A3 (en) | 2022-02-03 |
| AU2021299307A1 (en) | 2022-12-22 |
| CN116234571A (zh) | 2023-06-06 |
| JP2023534916A (ja) | 2023-08-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| McGirt et al. | Simvastatin increases endothelial nitric oxide synthase and ameliorates cerebral vasospasm resulting from subarachnoid hemorrhage | |
| Smith et al. | Botulinum toxin type A normalizes alterations in urothelial ATP and NO release induced by chronic spinal cord injury | |
| Sachs et al. | A new model of cuprizone-mediated demyelination/remyelination | |
| Eibl et al. | Effect of endothelin and endothelin receptor blockade on capillary permeability in experimental pancreatitis | |
| Shin et al. | Efficacy of perioperative intravenous iron therapy for transfusion in orthopedic surgery: a systematic review and meta-analysis | |
| Cavaletti | Chemotherapy‐induced peripheral neurotoxicity (CIPN): what we need and what we know | |
| Terasaki et al. | Comparison of end-to-end anastomosis and interposition graft during pancreatoduodenectomy with portal vein reconstruction for pancreatic ductal adenocarcinoma | |
| Paolin et al. | Oxidative damage after severe head injury and its relationship to neurological outcome | |
| LU91926I2 (fr) | Belimumab et ses dérivés pharmaceutiquement acceptables (Benlysta®) | |
| Hiroki et al. | Repeated administration of amitriptyline in neuropathic pain: modulation of the noradrenergic descending inhibitory system | |
| Lieder et al. | Cardioprotection by post-conditioning with exogenous triiodothyronine in isolated perfused rat hearts and isolated adult rat cardiomyocytes | |
| BR112021019520A2 (pt) | Composição farmacêutica, método para tratar a síndrome de hunter e uso de uma composição farmacêutica | |
| BR112023002458A2 (pt) | Métodos de tratamento da gota | |
| Nakahashi et al. | Role of nerve growth factor-tyrosine kinase receptor A signaling in paclitaxel-induced peripheral neuropathy in rats | |
| Patel et al. | High‐dose vitamin B12 in vasodilatory shock: a narrative review | |
| WO2024227174A3 (en) | Antibodies that bind ox40l and methods of use | |
| BR112023023558A2 (pt) | Anticorpos anti-tmprss6 e usos dos mesmos | |
| WO2022011110A3 (en) | Compositions and methods for the diagnosis and treatment of sars-cov-2 virus infection | |
| BRPI0416591A (pt) | métodos e reagentes para o tratamento de distúrbios inflamatórios | |
| Lohinai et al. | Biofilm lysine decarboxylase, a new therapeutic target for periodontal inflammation | |
| IL314179A (en) | Compositions and methods for the treatment of depression | |
| Dietrich et al. | Effects of aprotinin dosage on renal function: an analysis of 8,548 cardiac surgical patients treated with different dosages of aprotinin | |
| WO2023081235A3 (en) | Detection, staging, monitoring and treating a disease or a condition | |
| Shoshan et al. | Control of vasogenic edema in a brain tumor model: comparison between dexamethasone and superoxide dismutase | |
| BR112022026747A2 (pt) | Métodos de tratamento do distúrbio do espectro da neuromielite óptica |